A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)
Sponsor: Santen Inc.
This PHASE3 trial investigates Non-Infectious Uveitis of the Posterior Segment of the Eye and is currently completed. Santen Inc. leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2018 — Mar 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Santen Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Aurobindo Marg, India , Austin, United States , Bhubaneswar, India , Chennai, India , Daryāganj, India , Golden, United States , Graz, Austria , Hyderabad, India , Izmir, Turkey (Türkiye) and 15 more locations